Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints.It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart.
RA affects about 24.5 million people as of 2015. This is between 0.5 and 1.% of adults in the developed world with 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990.
25% of these new patients receive second-line biological treatment mostly TNF blockers or Rituximub.
~40% do not respond to anti TNF (also known as TNF blockers) treatment. This means: advancing disease, unneeded suffer and waste of financial recourses.
Currently, there is NO way to know in advance whether a patient will respond to either of the drug families.
Genefron Diagnostic Kit:
Genefron PDK IFR 300 (RA patients) – Used for predicting RA patients’ response to second line, anti-TNF family of drugs (such as Humira, Enbrell etc). The test is based on specific biomarkers (specific gene expression levels) of the patient immune system. The accuracy of the testis 88%, (Vs. 50%-60% random success) and it is approved by the Israeli MOH.
Genefron IFR 310 (RA patients is currently in clinical trials) is used for predicting RA patients’ response to B cell depletion drugs . The major goal of BCD therapy is to destroy autoimmune disease producing B cells in patients with autoimmune diseases, while at the same time retaining protective B cell immunity. Although it is widely used, the BCD mechanism of action is not fully clear. IFR310 presents ~90% accuracy vs. 60% today. Genefron expects IFR 310 commercial usage at Q3 2018.